NASDAQ:FATE - Fate Therapeutics Stock Price, Forecast & News

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Fate Therapeutics Inc (NASDAQ:FATE) issued its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the Zacks' consensus estimate of ($0.38) by $0.02. The biopharmaceutical company earned $2.43 million during the quarter, compared to analyst estimates of $1.75 million. Fate Therapeutics had a negative net margin of 900.24% and a negative return on equity of 48.94%. Fate Therapeutics's quarterly revenue was up 136.7% on a year-over-year basis. During the same quarter last year, the company earned ($0.31) earnings per share. View Fate Therapeutics' Earnings History.

Fate Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Fate Therapeutics.

16 brokers have issued 12-month price targets for Fate Therapeutics' shares. Their forecasts range from $20.00 to $33.00. On average, they anticipate Fate Therapeutics' share price to reach $25.56 in the next twelve months. This suggests that the stock has a possible downside of 0.3%. View Analyst Price Targets for Fate Therapeutics.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 2 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fate Therapeutics.

News headlines about FATE stock have been trending positive recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fate Therapeutics earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Fate Therapeutics.

Some companies that are related to Fate Therapeutics include BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), bluebird bio (BLUE), Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN) and Halozyme Therapeutics (HALO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), Energous (WATT), Juno Therapeutics (JUNO), Sangamo Therapeutics (SGMO), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Neurocrine Biosciences (NBIX), Crispr Therapeutics (CRSP), Exelixis (EXEL) and Immunomedics (IMMU).

Fate Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include TIAA FSB (0.03%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko and Redmile Group, Llc. View Institutional Ownership Trends for Fate Therapeutics.

FATE stock was purchased by a variety of institutional investors in the last quarter, including TIAA FSB. View Insider Buying and Selling for Fate Therapeutics.

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FATE stock can currently be purchased for approximately $25.65.

Fate Therapeutics has a market capitalization of $1.94 billion and generates $4.74 million in revenue each year. The biopharmaceutical company earns $-66,600,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Fate Therapeutics employs 104 workers across the globe.View Additional Information About Fate Therapeutics.

The official website for Fate Therapeutics is http://www.fatetherapeutics.com/.

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]